Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy

被引：0
|
作者：
Lee, A. [1 ]
Girling, B. [1 ]
Patel, G. [1 ]
Sawhney, P. [1 ]
Luong, M. [1 ]
Ohana, D. [1 ]
Forster, M. [1 ]
Lee, S. [1 ]
机构：
[1] Univ Coll London Hosp, Canc Div, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
immunotherapy; NSCLC; Toxicities;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA13.06
引用
下载
收藏
页码：S925 / S926
页数：2
相关论文
共 50 条
  • [31] Multiple Immune-Related Adverse Event Overlap in Two Patients Treated with Pembrolizumab
    Jenkins, Jessica D.
    Camara-Lemarroy, Carlos
    Joseph, Jeffrey T.
    Brust, Tyson
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2022, 49 (01) : 133 - 135
  • [32] Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.
    Elias, Roy
    Yan, Flora
    Singla, Nirmish
    Levonyack, Nicholas
    Formella, Joseph
    Christie, Alana
    Kapur, Payal
    Bowman, Alex Isaac
    Hammers, Hans J.
    Hannan, Raquibul
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [33] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sandigursky, Sabina
    Mor, Adam
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (10)
  • [34] RISK FACTORS OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB
    Eun, Y.
    Kim, I. Y.
    Kim, H.
    Ahn, J. K.
    Park, E. -J.
    Hwang, J.
    Jeong, H.
    Chai, J. Y.
    Cha, H. -S.
    Koh, E. -M.
    Lee, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1205 - 1205
  • [35] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sabina Sandigursky
    Adam Mor
    Current Rheumatology Reports, 2018, 20
  • [36] Rapid Onset of Immune-Related Adverse Events After Transition from Combination Pembrolizumab/Cytotoxic Chemotherapy to Pembrolizumab Monotherapy.
    Riopel, Nicholas
    Ye, Carrie
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1157 - 1158
  • [37] Cutaneous immune-related adverse events are undertreated in advanced cancer patients
    Chang, M.
    Otto, T.
    Jacoby, T.
    Thompson, L.
    Reynolds, K.
    Chen, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (09) : B10 - B10
  • [38] Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
    Albarran-Artahona, Victor
    Laguna, Juan-Carlos
    Gorria, Teresa
    Torres-Jimenez, Javier
    Pascal, Mariona
    Mezquita, Laura
    DIAGNOSTICS, 2022, 12 (09)
  • [39] Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients
    Kawai, Taketo
    Sato, Yusuke
    Makino, Katsuhiro
    Yamada, Yuta
    Nomiya, Akira
    Nakamura, Masaki
    Yamada, Daisuke
    Suzuki, Motofumi
    Igawa, Yasuhiko
    Kume, Haruki
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 114 - 115
  • [40] Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab
    Kothari, Shawn
    Bagley, Stephen
    Aggarwal, Charu
    Baum, Joshua
    Alley, Evan
    Evans, Tracey
    Kosteva, John
    Ciunci, Christine
    Thompson, Jeffrey
    Stonehouse-Lee, Susan
    Sherry, Victoria
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    Dilullo, Gloria
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1290 - S1290
12345